RESEARCH-USE BIOSIMILAR ANTIBODY
Demcizumab
Monoclonal antibody · IgG2
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
TARGETDLL4
YMonoclonal antibody
CATALOGSC-BS-634
CATALOG NUMBERSC-BS-634
MOLECULAR WEIGHTApprox. 145.36 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
Demcizumab is a recombinant research-use antibody directed against DLL4.